The Global Cancer Diagnostics Market Size accounted for USD 142.3 Billion in 2022 and is estimated to achieve a market size of USD 276.2 Billion by 2032 growing at a CAGR of 7.8% from 2024 to 2032.
Cancer Diagnostics Market Highlights
- Global cancer diagnostics market revenue is poised to garner USD 276.2 billion by 2032 with a CAGR of 7.8% from 2024 to 2032
- North America cancer diagnostics market value occupied around USD 58.3 billion in 2022
- Asia-Pacific cancer diagnostics market growth will record a CAGR of more than 8.5% from 2024 to 2032
- Among product, the consumables sub-segment generated USD 88.2 billion revenue in 2022
- Based on end-use, the hospitals sub-segment generated 52% cancer diagnostics market share in 2022
- Integration of technology can enhance diagnostic capabilities and remote patient care is a popular cancer diagnostics market trend that fuels the industry demand
Cancer diagnosis is the process of determining the presence of cancer cells in the body. It entails a battery of tests and procedures to establish whether a person has cancer, the type of disease, and its stage of progression. Imaging tests, biopsies, blood tests, and genetic testing are among the most common diagnostic approaches. Imaging tests, such as X-rays, CT scans, MRIs, and ultrasounds, are used to examine the body's internal structures for malignancy. Biopsies are the removal of tissue samples for examination under a microscope to detect cancer cells. Blood tests can detect abnormal amounts of specific compounds in the blood, which may suggest the existence of cancer. Genetic testing examines DNA for mutations linked to cancer.
Early detection through cancer diagnostics is crucial for successful treatment and improved outcomes. Regular screenings and prompt medical attention when symptoms arise can increase the chances of detecting cancer at an early stage, when treatment is often more effective.
Global Cancer Diagnostics Market Dynamics
Market Drivers
- Increasing global population and aging demographic lead to higher cancer cases
- Innovations in imaging techniques, biomarkers, and genetic testing improve accuracy and early detection
- Growing public understanding of cancer and regular checkups drive demand for diagnostics
- Government support and favorable reimbursement policies encourage diagnostic services
Market Restraints
- Diagnostic procedures can be expensive, limiting accessibility, especially in developing countries
- Shortage of skilled healthcare professionals in certain regions can hinder diagnostic services
- Issues related to genetic testing and patient privacy can pose challenges
Market Opportunities
- Advancements in genomics enable tailored diagnostic approaches for individual patients
- Portable diagnostic devices can improve accessibility and speed of diagnosis
- Growing economies in Asia, Africa, and Latin America offer significant market potential for diagnostic services
Cancer Diagnostics Market Report Coverage
| Market |
Cancer Diagnostics Market
|
| Cancer Diagnostics Market Size 2022 |
USD 142.3 Billion
|
| Cancer Diagnostics Market Forecast 2032 |
USD 276.2 Billion |
| Cancer Diagnostics Market CAGR During 2023 - 2032 |
7.8% |
| Cancer Diagnostics Market Analysis Period |
2020 - 2032 |
Cancer Diagnostics Market Base Year
|
2022 |
| Cancer Diagnostics Market Forecast Data |
2023 - 2032 |
| Segments Covered |
By Product, By Type, By Test Type, By Application, By End-Use, And By Geography
|
| Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
Roche Diagnostics, Thermo Fisher Scientific, Inc., Illumina, Inc., Siemens Healthcare, Agilent Technologies, Inc., bioMérieux SA, QIAGEN N.V., Abbott Laboratories, Inc., GE Healthcare, Philips Healthcare, Becton, and Dickinson and Company.
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Cancer Diagnostics Market Insights
Developing predominance of oncologic cases, steady innovative progressions in diagnostics, and expanding demand for successful screening tests are a portion of the prime factors prodding demand for screening devices and strategies over the world. Rising mindfulness and strong government activities are some extra factors foreseen to support market development amid the forecast period.
Cancer growth is one of the main sources of deaths over the world and predominance of the disease has been heightening at an alarming rate. In this manner, healthcare professional’s experts are concentrating on improvement of compelling demonstrative and treatment answers for check commonness level. Early identification of disease, increases the success rate of treatment regimens. Accordingly, healthcare agencies and market players, through different mindfulness programs, are advancing routine check-ups.
The breast cancer growth portion caught the biggest in the disease diagnostics market forecast period. Mammography is the most well-known and prevalent screening test utilized for breast tumour screening. As per the United States Preventive Services Task Force (USPSTF), ladies aged somewhere in the range of 50 and 74 years are at a higher danger of creating breast malignant growth. Along these lines, USPSTF prescribes ladies over 40 years old to experience mammography every two years.
Also, numerous associations, for example, the National Breast Cancer Foundation, Inc. are embraced activities to spread mindfulness in regards to breast cancer growth, advantages of early location, and accessible treatment alternatives. Increasing cognizance of the populace, combined with campaigns promoting routine mammography, is bringing about extreme demand for imaging arrangements in breast disease screening.
Cancer Diagnostics Market Segmentation
The worldwide market for cancer diagnostics is split based on product, type, test type, application, end-uses, and geography.
Cancer Diagnostics By Product
- Instruments
- Pathology-based Instruments
- Slide Staining Systems
- Tissue Processing Systems
- Cell Processors
- PCR Instruments
- NGS Instruments
- Microarrays
- Other Pathology-based Instruments
- Imaging Instruments
- Others
- Consumables
- Antibodies
- Kits & reagents
- Probes
- Others
- Services
According to cancer diagnostics industry analysis, the market is divided into three segments; instruments, consumables, and services. Consumables make up the majority of this market. Consumables such as reagents, kits, and sample preparation supplies are required for performing diagnostic tests. They are used in conjunction with diagnostic devices to examine biological samples for the presence of cancer cells or biomarkers. The high consumption rate of consumables, driven by rising demand for cancer diagnostics, contributes considerably to the growth of this market sector.
Cancer Diagnostics By Type
- IVD
- By Type
- Diagnosis
- Early Detection
- Therapy Selection
- Monitoring
- By Technology
- LDT
- Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Positron Emission Tomography (PET)
- Mammography
- Ultrasound
- Others
The cancer diagnostics market is divided into three major segments; in vitro diagnostics (IVD), laboratory-developed tests (LDT), and imaging. IVD, which includes evaluating biological samples outside the body, now controls the market. This is mostly owing to its widespread availability, standardized processes, and ability to offer prompt and reliable diagnoses. However, LDTs developed and administered in clinical laboratories are gaining popularity due to their flexibility and potential for personalised testing.
Cancer Diagnostics By Test Type
- Biopsy
- Fine-needle Aspiration
- Core Biopsy
- Surgical Biopsy
- Skin Biopsy /Punch Biopsy
- Others
- Others
In the cancer diagnostics market forecast, the biopsy category is expected to be particularly influential. Fine-needle aspiration (FNA) is unique among biopsy subcategories in that it is less invasive, rapid to perform, and can yield a definitive diagnosis with fewer consequences. Core biopsy, while more invasive than FNA, is predicted to develop significantly due to its ability to provide larger tissue samples, which improves diagnostic accuracy. The demand for skin and surgical biopsies remains high due to their importance in specific cancer types, with an increasing emphasis on early-stage cancer detection driving overall market growth.
Cancer Diagnostics By Application
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
Breast cancer diagnostics have the highest market share. This can be linked to a variety of causes, including public awareness campaigns and educational activities that have raised knowledge about the need of early breast cancer detection and screening. This has resulted in a greater number of women seeking diagnostic treatments. Early detection programs, such as mammograms, supported by the government and directed by healthcare providers, have been critical in detecting breast cancer in its early stages. These initiatives encourage women to have regular screenings, which adds to the need for breast cancer diagnoses. The development and availability of advanced diagnostic technologies, such as digital mammography, ultrasound, and MRI, have improved the accuracy and sensitivity of breast cancer detection. These technologies provide more precise information about the presence and extent of tumors, enabling earlier diagnosis and more effective treatment.
Cancer Diagnostics By End-Use
- Hospitals
- Laboratories
- Others
Hospitals account for almost 52% of the cancer diagnostics market, reflecting the increased demand for enhanced diagnostic technologies in clinical settings. Hospitals are generally the initial point of contact for patients seeking cancer diagnosis, and they use cutting-edge imaging and biopsy tools to discover and screen disease early. Furthermore, hospitals have interdisciplinary teams, including oncologists and radiologists, who work together to provide comprehensive diagnostic care. Their access to advanced laboratory equipment and competent people assures precise results, which contributes to their market dominance. Furthermore, the increasing global prevalence of cancer cases and the emphasis on early detection to enhance patient outcomes reinforce hospitals' dominant position in this industry.
Cancer Diagnostics Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Cancer Diagnostics Market Regional Analysis
North America ruled the industry by capturing the biggest revenue share offer of 41% in 2023. Nearness of various biotechnologies just as medicinal gadget organizations in the locale is one of the prime elements driving the diagnostics sector in the region. North America is relied upon to proceed with its lead all through the estimate time frame inferable from elements, for example, more prominent subsidizing accessible for research and development projects and high reception of cutting edge innovations.
Asia Pacific is relied upon to show the most astounding development sooner rather than later because of quality of a substantial patient pool, accessibility of skilled experts at a relatively lower cost, and a characterized administrative structure favoring expedited product approvals. Besides, the blasting tourism the travel industry in nations, for example, India, China, and Malaysia are relied upon to help demand for oncological screening.
Cancer Diagnostics Market Players
Some of the top cancer diagnostics companies offered in our report includes Roche Diagnostics, Thermo Fisher Scientific, Inc., Illumina, Inc., Siemens Healthcare, Agilent Technologies, Inc., bioMérieux SA, QIAGEN N.V., Abbott Laboratories, Inc., GE Healthcare, Philips Healthcare, Becton, and Dickinson and Company.
CHAPTER 1. Industry Overview of Cancer Diagnostics Market
1.1. Definition and Scope
1.1.1. Definition of Cancer Diagnostics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Cancer Diagnostics Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Cancer Diagnostics Market By Product
1.2.3. Cancer Diagnostics Market By Type
1.2.4. Cancer Diagnostics Market By Test Type
1.2.5. Cancer Diagnostics Market By Application
1.2.6. Cancer Diagnostics Market By End-Use
1.2.7. Cancer Diagnostics Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Cancer Diagnostics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Cancer Diagnostics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Cancer Diagnostics Market By Product
4.1. Introduction
4.2. Cancer Diagnostics Revenue By Product
4.2.1. Cancer Diagnostics Revenue (USD Million) and Forecast, By Product, 2020-2032
4.2.2. Instruments
4.2.2.1. Instruments Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.2. Pathology-Based Instruments
4.2.2.2.1. Pathology-Based Instruments Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.2.2. Slide Staining Systems
4.2.2.2.2.1. Slide Staining Systems Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.2.3. Tissue Processing Systems
4.2.2.2.3.1. Tissue Processing Systems Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.2.4. Cell Processors
4.2.2.2.4.1. Cell Processors Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.2.5. PCR Instruments
4.2.2.2.5.1. PCR Instruments Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.2.6. NGS Instruments
4.2.2.2.6.1. NGS Instruments Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.2.7. Microarrays
4.2.2.2.7.1. Microarrays Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.2.8. Other Pathology-based Instruments
4.2.2.2.8.1. Other Pathology-based Instruments Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.3. Imaging Instruments
4.2.2.3.1. Imaging Instruments Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.2.4. Others
4.2.2.4.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.3. Consumables
4.2.3.1. Consumables Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.3.2. Antibodies
4.2.3.2.1. Antibodies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.3.3. Kits & reagents
4.2.3.3.1. Kits & reagents Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.3.4. Probes
4.2.3.4.1. Probes Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.3.5. Others
4.2.3.5.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.4. Services
4.2.4.1. Services Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 5. Cancer Diagnostics Market By Type
5.1. Introduction
5.2. Cancer Diagnostics Revenue By Type
5.2.1. Cancer Diagnostics Revenue (USD Million) and Forecast, By Type, 2020-2032
5.2.2. IVD
5.2.2.1. IVD Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2. By Type
5.2.2.2.1. By Type Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2.2. Diagnosis
5.2.2.2.2.1. Diagnosis Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2.3. Early Detection
5.2.2.2.3.1. Early Detection Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2.4. Therapy Selection
5.2.2.2.4.1. Therapy Selection Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2.5. Monitoring
5.2.2.2.5.1. Monitoring Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3. By Technology
5.2.2.3.1. By Technology Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3.2. Polymerase Chain Reaction (PCR)
5.2.2.3.2.1. Polymerase Chain Reaction (PCR) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3.3. In Situ Hybridization (ISH)
5.2.2.3.3.1. In Situ Hybridization (ISH) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3.4. Immunohistochemistry (IHC)
5.2.2.3.4.1. Immunohistochemistry (IHC) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3.5. Next-generation Sequencing (NGS)
5.2.2.3.5.1. Next-generation Sequencing (NGS) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3.6. Microarrays
5.2.2.3.6.1. Microarrays Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3.7. Flow Cytometry
5.2.2.3.7.1. Flow Cytometry Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3.8. Immunoassays
5.2.2.3.8.1. Immunoassays Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3.9. Other IVD Testing Technologies
5.2.2.3.9.1. Other IVD Testing Technologies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3. LDT
5.2.3.1. LDT Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4. Imaging
5.2.4.1. Imaging Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4.1.1. Magnetic Resonance Imaging (MRI)
5.2.4.1.1.1. Magnetic Resonance Imaging (MRI) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4.1.2. Computed Tomography (CT)
5.2.4.1.2.1. Computed Tomography (CT) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4.1.3. Positron Emission Tomography (PET)
5.2.4.1.3.1. Positron Emission Tomography (PET) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4.1.4. Mammography
5.2.4.1.4.1. Mammography Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4.1.5. Ultrasound
5.2.4.1.5.1. Ultrasound Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4.1.6. Others
5.2.4.1.6.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 6. Cancer Diagnostics Market By Test Type
6.1. Introduction
6.2. Cancer Diagnostics Revenue By Test Type
6.2.1. Cancer Diagnostics Revenue (USD Million) and Forecast, By Test Type, 2020-2032
6.2.2. Biopsy
6.2.2.1. Biopsy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.2.2. Fine-needle Aspiration
6.2.2.2.1. Fine-needle Aspiration Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.2.3. Core Biopsy
6.2.2.3.1. Core Biopsy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.2.4. Surgical Biopsy
6.2.2.4.1. Surgical Biopsy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.2.5. Skin Biopsy /Punch Biopsy
6.2.2.5.1. Skin Biopsy /Punch Biopsy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.2.6. Others
6.2.2.6.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.3. Others
6.2.3.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 7. Cancer Diagnostics Market By Application
7.1. Introduction
7.2. Cancer Diagnostics Revenue By Application
7.2.1. Cancer Diagnostics Revenue (USD Million) and Forecast, By Application, 2020-2032
7.2.2. Breast Cancer
7.2.2.1. Breast Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.3. Colorectal Cancer
7.2.3.1. Colorectal Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.4. Cervical Cancer
7.2.4.1. Cervical Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.5. Lung Cancer
7.2.5.1. Lung Cancer Companies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.6. Prostate Cancer
7.2.6.1. Prostate Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.7. Skin Cancer
7.2.7.1. Skin Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.8. Blood Cancer
7.2.8.1. Blood Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.9. Kidney Cancer
7.2.9.1. Kidney Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.10. Liver Cancer
7.2.10.1. Liver Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.11. Pancreatic Cancer
7.2.11.1. Pancreatic Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.12. Ovarian Cancer
7.2.12.1. Ovarian Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.13. Others
7.2.13.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 8. Cancer Diagnostics Market By End-Use
8.1. Introduction
8.2. Cancer Diagnostics Revenue By End-Use
8.2.1. Cancer Diagnostics Revenue (USD Million) and Forecast, By End-Use, 2020-2032
8.2.2. Hospitals
8.2.2.1. Hospitals Market Revenue (USD Million) and Growth Rate (%), 2020-2032
8.2.3. Laboratories
8.2.3.1. Laboratories Market Revenue (USD Million) and Growth Rate (%), 2020-2032
8.2.4. Others
8.2.4.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 9. North America Cancer Diagnostics Market By Country
9.1. North America Cancer Diagnostics Market Overview
9.2. U.S.
9.2.1. U.S. Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
9.2.2. U.S. Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
9.2.3. U.S. Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
9.2.4. U.S. Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
9.2.5. U.S. Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
9.3. Canada
9.3.1. Canada Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
9.3.2. Canada Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
9.3.3. Canada Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
9.3.4. Canada Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
9.3.5. Canada Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
9.4. North America PEST Analysis
CHAPTER 10. Europe Cancer Diagnostics Market By Country
10.1. Europe Cancer Diagnostics Market Overview
10.2. U.K.
10.2.1. U.K. Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
10.2.2. U.K. Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
10.2.3. U.K. Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
10.2.4. U.K. Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
10.2.5. U.K. Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
10.3. Germany
10.3.1. Germany Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
10.3.2. Germany Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
10.3.3. Germany Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
10.3.4. Germany Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
10.3.5. Germany Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
10.4. France
10.4.1. France Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
10.4.2. France Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
10.4.3. France Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
10.4.4. France Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
10.4.5. France Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
10.5. Spain
10.5.1. Spain Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
10.5.2. Spain Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
10.5.3. Spain Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
10.5.4. Spain Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
10.5.5. Spain Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
10.6. Rest of Europe
10.6.1. Rest of Europe Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
10.6.2. Rest of Europe Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
10.6.3. Rest of Europe Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
10.6.4. Rest of Europe Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
10.6.5. Rest of Europe Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
10.7. Europe PEST Analysis
CHAPTER 11. Asia Pacific Cancer Diagnostics Market By Country
11.1. Asia Pacific Cancer Diagnostics Market Overview
11.2. China
11.2.1. China Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
11.2.2. China Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
11.2.3. China Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
11.2.4. China Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
11.2.5. China Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
11.3. Japan
11.3.1. Japan Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
11.3.2. Japan Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
11.3.3. Japan Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
11.3.4. Japan Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
11.3.5. Japan Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
11.4. India
11.4.1. India Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
11.4.2. India Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
11.4.3. India Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
11.4.4. India Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
11.4.5. India Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
11.5. Australia
11.5.1. Australia Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
11.5.2. Australia Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
11.5.3. Australia Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
11.5.4. Australia Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
11.5.5. Australia Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
11.6. South Korea
11.6.1. South Korea Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
11.6.2. South Korea Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
11.6.3. South Korea Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
11.6.4. South Korea Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
11.6.5. South Korea Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
11.7. Rest of Asia-Pacific
11.7.1. Rest of Asia-Pacific Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
11.7.2. Rest of Asia-Pacific Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
11.7.3. Rest of Asia-Pacific Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
11.7.4. Rest of Asia-Pacific Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
11.7.5. Rest of Asia-Pacific Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
11.8. Asia Pacific PEST Analysis
CHAPTER 12. Latin America Cancer Diagnostics Market By Country
12.1. Latin America Cancer Diagnostics Market Overview
12.2. Brazil
12.2.1. Brazil Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
12.2.2. Brazil Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
12.2.3. Brazil Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
12.2.4. Brazil Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
12.2.5. Brazil Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
12.3. Mexico
12.3.1. Mexico Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
12.3.2. Mexico Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
12.3.3. Mexico Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
12.3.4. Mexico Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
12.3.5. Mexico Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
12.4. Rest of Latin America
12.4.1. Rest of Latin America Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
12.4.2. Rest of Latin America Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
12.4.3. Rest of Latin America Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
12.4.4. Rest of Latin America Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
12.4.5. Rest of Latin America Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
12.5. Latin America PEST Analysis
CHAPTER 13. Middle East & Africa Cancer Diagnostics Market By Country
13.1. Middle East & Africa Cancer Diagnostics Market Overview
13.2. GCC
13.2.1. GCC Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
13.2.2. GCC Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
13.2.3. GCC Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
13.2.4. GCC Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
13.2.5. GCC Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
13.3. South Africa
13.3.1. South Africa Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
13.3.2. South Africa Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
13.3.3. South Africa Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
13.3.4. South Africa Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
13.3.5. South Africa Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
13.4. Rest of Middle East & Africa
13.4.1. Rest of Middle East & Africa Cancer Diagnostics Revenue (USD Million) and Forecast By Type, 2020-2032
13.4.2. Rest of Middle East & Africa Cancer Diagnostics Revenue (USD Million) and Forecast By Product, 2020-2032
13.4.3. Rest of Middle East & Africa Cancer Diagnostics Revenue (USD Million) and Forecast By Test Type, 2020-2032
13.4.4. Rest of Middle East & Africa Cancer Diagnostics Revenue (USD Million) and Forecast By Application, 2020-2032
13.4.5. Rest of Middle East & Africa Cancer Diagnostics Revenue (USD Million) and Forecast By End-Use, 2020-2032
13.5. Middle East & Africa PEST Analysis
CHAPTER 14. Player Analysis Of Cancer Diagnostics Market
14.1. Cancer Diagnostics Market Company Share Analysis
14.2. Competition Matrix
14.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
14.2.2. New Product Launches and Product Enhancements
14.2.3. Mergers And Acquisition In Global Cancer Diagnostics Market
14.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 15. Company Profile
15.1. Roche Diagnostics
15.1.1. Company Snapshot
15.1.2. Business Overview
15.1.3. Financial Overview
15.1.3.1. Revenue (USD Million), 2022
15.1.3.2. Roche Diagnostics 2022 Cancer Diagnostics Business Regional Distribution
15.1.4. Product /Service and Specification
15.1.5. Recent Developments & Business Strategy
15.2. Thermo Fisher Scientific, Inc.
15.3. Illumina, Inc.
15.4. Siemens Healthcare
15.5. Agilent Technologies, Inc.
15.6. bioMérieux SA
15.7. QIAGEN N.V.
15.8. Abbott Laboratories, Inc.
15.9. GE Healthcare
15.10. Philips Healthcare
15.11. Becton, and Dickinson and Company
